Table 2

Predictors for functional outcome

Good outcome (mRS ≤ 2)


Exp(Coef)

95% CI

P-value


Univariate


Age

0.834

0.794 to 0.872

< 0.0001

SEX (female)

1.265

0.554 to 1.864

0.57645

Hospital LOS

0.759

0.281 to 0.866

0.04397

Length of ventilation

0.410

0.113 to 0.641

0.01202

Length of ventilation (per increasing day)

0.974

0.913 to 1.061

0.09441

TISS-28 on Day 1

< 21

2.746

1.935 to 4.391

0.00666

20 to 40

1.273

0.764 to 1.812

0.21932

> 40

0.715

0.621 to 0.944

0.00181

TISS-28 at discharge

< 21

2.187

1.453 to 3.812

0.01215

20 to 40

1.234

0.218 to 2.187

0.23156

> 40

0.711

0.451 to 0.857

0.00017

Ischemia

0.724

0.485 to 0.932

0.04275

ICH

0.743

0.573 to 0.935

0.02046

SAH

0.636

0.273 to 1.198

0.63532

Meningoencephalitis

1.412

0.996 to 3.238

0.12432

Epilepsy

1.433

0.233 to 2.346

0.73255

GBS/MG

3.623

1.124 to 13.327

0.00145

Neurodeg./Encephalopathy

0.680

0.274 to 1.019

0.05723

Neoplasm

0.692

0.371 to 0.856

0.00039

Intoxication

5.809

1.832 to 7.483

0.03881


Multivariate


Age

0.786

0.435 to 0.823

0.00245

Hospital LOS

0.509

0.272 to 1.279

0.17647

Length of ventilation

0.681

0.475 to 0.912

0.00354

TISS-28 on Day 1 > 40

0.815

0.578 to 0.931

0.00187

Ischemia

0.345

0.245 to 1.101

0.11458

ICH

0.643

0.218 to 0.877

0.03874

GBS/MG

2.215

2.006 TO 3.214

0.03329

Neurodeg./Encephalopathy

0.705

0.297 to 1.354

0.15478

Neoplasm

0.687

0.354 to 0.934

0.04875

Intoxication

1.399

0.964 to 2.648

0.27261


Univariate and multivariate regression analysis for parameters predicting a good functional outcome (mRS 0 to 2) one year after neurocritical care. Analysis of all patients receiving specialized neurocritical care (n = 666). Parameters that reached significance (P < 0.05) are expressed in bold. Parameters that showed a statistical trend (P < 0.1) in the univariate analysis are expressed in italics.

Abbreviations: CI, confidence interval; LOS, length of stay; ICH, intracranial hemorrhage; SAH, subarachnoid hemorrhage; GBS, Guillain-Barré syndrome; MG, myasthenia gravis; Neurodeg, neurodegenerative disease

Kiphuth et al. Critical Care 2010 14:R136   doi:10.1186/cc9192

Open Data